Ubenimex in the treatment of acute nonlymphocytic leukemia in adults
โ Scribed by A. Urabe; Y. Mutoh; H. Mizoguchi; F. Takaku; N. Ogawa
- Publisher
- Springer
- Year
- 1993
- Tongue
- English
- Weight
- 414 KB
- Volume
- 67
- Category
- Article
- ISSN
- 0939-5555
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patie
Recent treatment strategies in adult ALL mainly include (1) intensification of induction and consolidation chemotherapy, (2) molecular targeting, particularly in Ph/bcr abl pos-ALL, (3) antibody therapy and (4) extension of stem cell transplantation (SCT). New diagnostic tools are used to refine def
High-dose cytosine arabinoside (Ara-C) was used in adult patients with refractory acute nonlymphoblastic leukemia, either alone (3 g/m2 every 12 h X 12 doses) or with 3 additional days of anthracycline antibiotics. The systemic toxicities were similar for both groups without an increase in the group